S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:PRNBPrincipia Biopharma Stock Price, Forecast & News

$90.74
-1.06 (-1.15 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$89.46
Now: $90.74
$92.72
50-Day Range
$56.00
MA: $74.32
$91.89
52-Week Range
$25.35
Now: $90.74
$95.15
Volume391,859 shs
Average Volume392,518 shs
Market Capitalization$3.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Read More
Principia Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRNB
CUSIPN/A
CIKN/A
Phone650-416-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$35.16 million
Book Value$10.95 per share

Profitability

Net Income$-53,790,000.00

Miscellaneous

Employees65
Market Cap$3.01 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$90.74
-1.06 (-1.15 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRNB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Principia Biopharma (NASDAQ:PRNB) Frequently Asked Questions

How has Principia Biopharma's stock price been impacted by Coronavirus?

Principia Biopharma's stock was trading at $53.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRNB shares have increased by 68.4% and is now trading at $90.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Principia Biopharma?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Principia Biopharma
.

When is Principia Biopharma's next earnings date?

Principia Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Principia Biopharma
.

How were Principia Biopharma's earnings last quarter?

Principia Biopharma Inc (NASDAQ:PRNB) released its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.03) by $1.34.
View Principia Biopharma's earnings history
.

What price target have analysts set for PRNB?

7 equities research analysts have issued 12 month price objectives for Principia Biopharma's shares. Their forecasts range from $76.00 to $112.00. On average, they expect Principia Biopharma's share price to reach $92.67 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for Principia Biopharma
.

Has Principia Biopharma been receiving favorable news coverage?

News stories about PRNB stock have trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Principia Biopharma earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Principia Biopharma
.

Are investors shorting Principia Biopharma?

Principia Biopharma saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,360,000 shares, an increase of 45.5% from the June 15th total of 2,310,000 shares. Based on an average daily volume of 378,500 shares, the days-to-cover ratio is presently 8.9 days.
View Principia Biopharma's Short Interest
.

Who are some of Principia Biopharma's key competitors?

What other stocks do shareholders of Principia Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Micron Technology (MU), Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Taiwan Semiconductor Mfg. (TSM) and Activision Blizzard (ATVI).

Who are Principia Biopharma's key executives?

Principia Biopharma's management team includes the following people:
  • Dr. Alan B. Colowick Ph.D., M.D., M.P.H., Exec. Chairman (Age 57)
  • Mr. Martin Babler, CEO & Director (Age 54)
  • Mr. Christopher Y. Chai, Chief Financial Officer (Age 52)
  • Ms. Stefani A. Wolff, Chief Devel. Officer (Age 57)
  • Dr. David M. Goldstein, Chief Scientific Officer (Age 53)

When did Principia Biopharma IPO?

(PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Principia Biopharma's stock symbol?

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Who are Principia Biopharma's major shareholders?

Principia Biopharma's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.92%), Cormorant Asset Management LP (4.79%), BVF Inc. IL (4.47%), Vanguard Group Inc. (3.77%), Avidity Partners Management LP (1.65%) and Goldman Sachs Group Inc. (1.13%). Company insiders that own Principia Biopharma stock include Alan Colowick, Christopher Y Chai, Daniel J Becker, David Goldstein, David M Goldstein, Dolca Thomas, Leaf Ventures Ii LP New, Martin Babler, Orbimed Advisors Llc, Plc Glaxosmithkline, Roy C Hardiman, Simeon George, Srinivas Akkaraju and Stefani Wolff.
View institutional ownership trends for Principia Biopharma
.

Which institutional investors are selling Principia Biopharma stock?

PRNB stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Driehaus Capital Management LLC, BVF Inc. IL, Artal Group S.A., EAM Investors LLC, First Trust Advisors LP, Alps Advisors Inc., and Candriam Luxembourg S.C.A.. Company insiders that have sold Principia Biopharma company stock in the last year include Alan Colowick, Christopher Y Chai, David Goldstein, David M Goldstein, Dolca Thomas, Martin Babler, Roy C Hardiman, and Stefani Wolff.
View insider buying and selling activity for Principia Biopharma
.

Which institutional investors are buying Principia Biopharma stock?

PRNB stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Goldman Sachs Group Inc., Logos Global Management LP, Vanguard Group Inc., Tekla Capital Management LLC, Healthcare of Ontario Pension Plan Trust Fund, Athanor Capital LP, and California Public Employees Retirement System. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George, and Srinivas Akkaraju.
View insider buying and selling activity for Principia Biopharma
.

How do I buy shares of Principia Biopharma?

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Principia Biopharma's stock price today?

One share of PRNB stock can currently be purchased for approximately $90.74.

How big of a company is Principia Biopharma?

Principia Biopharma has a market capitalization of $3.01 billion and generates $35.16 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.

What is Principia Biopharma's official website?

The official website for Principia Biopharma is www.principiabio.com.

How can I contact Principia Biopharma?

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.